Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)
about
Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerabilityStructural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutantImpact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activitiesGenotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapyAnti-human immunodeficiency virus type 1 activity of novel 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives.A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in repClinical utility of current NNRTIs and perspectives of new agents in this class under development.HIV-1 antiretroviral drug therapy.Inhibition of HIV-1 reverse transcription: basic principles of drug action and resistance.Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase.Clinical significance of human immunodeficiency virus type 1 replication fitness.The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.Reverse transcriptase inhibitors as potential colorectal microbicides.Mechanism of HIV antiretroviral drugs progress toward drug resistance.Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group.A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance.Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication.Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.Abacavir hypersensitivity reaction.
P2860
Q24628212-8FFAF6BB-8345-4562-B0CC-8CB5375E6879Q27638329-F5AF1D1D-91CA-4CF4-B004-8279FEC47C99Q33624190-C77D9165-1011-460C-BCB2-5694B62208C4Q33714377-674300A4-8682-496C-A59B-AE69D06C4867Q33815628-BBA25341-94AF-4F56-B6E6-ADC017C6CA04Q33851627-E0785760-ACCA-4D8E-B2F7-40E39C26F957Q33873983-1D74A79D-FB5C-456B-95F4-9640911F02B3Q33906239-F1C6A7A6-5168-4B1E-B3BD-5AA1AD8A0D02Q33980528-F06849FC-9CC4-4F2A-AAEF-50657EDFFA30Q34145448-23B50A3A-FE3C-4ED8-8ADA-8BF9192EDCF1Q35742512-2CA34E55-644B-4838-B5DB-FF85E32B0F50Q35794241-71EF0B43-D373-4DD0-A160-E04B731DB103Q35842270-8D93C08E-2E8E-4812-ABCE-5176F83CC1BAQ35853012-1E0C0B37-BADC-4B7C-839D-1D73923EF7D0Q35917530-FF1901ED-DB64-4BE6-995B-08D6B28380E7Q36292765-C160CF3A-54B6-4B9E-AF98-7AF148DD24FCQ36632128-7E3F4435-8B8A-4B32-85FF-FD3B34375265Q36969857-489C54D9-8FD8-419B-BE2A-17FEC1E6ED5BQ37018369-E2B33910-FEB5-4036-B0C6-C6B5B8A21B0BQ37190754-FEE32B83-EC2C-4706-AAC2-A791EC687A9DQ37961181-489952EF-3D15-4306-A556-5DFA364D1BEBQ39537282-3ED49A35-6BE0-422C-9780-30C77DC4148EQ39683954-B3292B80-99AF-4160-9DA0-47905458715AQ39699409-F8434A05-9CEE-44BA-9E65-78E11C1B374FQ40410591-1F5BA28D-2C15-4E05-80BB-1C9516C71939Q43774080-BFC30D98-BA56-4FE6-B123-1D9CEEAE92CDQ43933908-62948892-6DD5-4D31-8D53-53940430F63B
P2860
Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Delavirdine susceptibilities a ...... virdine monotherapy (ACTG 260)
@ast
Delavirdine susceptibilities a ...... virdine monotherapy (ACTG 260)
@en
Delavirdine susceptibilities a ...... virdine monotherapy (ACTG 260)
@nl
type
label
Delavirdine susceptibilities a ...... virdine monotherapy (ACTG 260)
@ast
Delavirdine susceptibilities a ...... virdine monotherapy (ACTG 260)
@en
Delavirdine susceptibilities a ...... virdine monotherapy (ACTG 260)
@nl
prefLabel
Delavirdine susceptibilities a ...... virdine monotherapy (ACTG 260)
@ast
Delavirdine susceptibilities a ...... virdine monotherapy (ACTG 260)
@en
Delavirdine susceptibilities a ...... virdine monotherapy (ACTG 260)
@nl
P2093
P2860
P1476
Delavirdine susceptibilities a ...... virdine monotherapy (ACTG 260)
@en
P2093
J Holden-Wiltse
L M Demeter
M A Fischl
P M Meehan
R C Reichman
R W Shafer
W W Freimuth
P2860
P356
10.1128/AAC.44.3.794-797.2000
P407
P577
2000-03-01T00:00:00Z